Hims & Hers product display.
his and hers
Digital Pharmacy Startups his and her health The company announced on Monday that it is launching a compounded GLP-1 weight loss injection.
The company offers a range of direct-to-consumer treatments for conditions such as erectile dysfunction and hair loss, and launched a weight-loss program in December. But GLP-1 drugs — drugs that have soared in popularity such as Ozempic and Wegovy — had not previously been offered as part of the program.
Customers can obtain compounded GLP-1 medications through prescription from licensed healthcare providers on the Hims & Hers platform. Hims & Hers said it plans to make the branded GLP-1 drug available to customers once supplies stabilize.
The company’s oral drug kit starts at $79 per month, and its compounded GLP-1 injection starts at $199 per month.
Even before adding GLP-1 Complex to its product portfolio, Hims & Hers said in its fourth-quarter earnings report that it expected its weight-loss program to bring in more than $100 million in revenue by the end of 2025. guidance in its next earnings report.
The GLP-1 market has so far been dominated by pharmaceutical giants Novo NordiskThe drugs have faced supply constraints in recent months as they win expanded approval from health regulators and expand medical coverage.
GLP-1 suppresses appetite and regulates blood sugar in humans by mimicking hormones produced in the gut. When these drugs are in short supply, some manufacturers can prepare compounded versions of them, as long as they meet certain FDA requirements.
in a Released in JanuaryThe FDA says patients should not use compounded GLP-1 drugs if they have access to an approved drug like Wegovy.
Hims & Hers CEO Andrew Dudum told CNBC the company is “confident” customers will have access to a steady supply of compounded medications.
Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and working with one of the largest FDA-regulated generic drug manufacturers in the United States.
“We have a level of exclusivity on the facility that will ensure a stable volume and supply for our consumers,” he said in an interview.
About The Author
